

## AXIRON NET SALES, QUARTER TO 30 SEPTEMBER 2014

Acrux (ASX: ACR) today confirmed that Eli Lilly reported global Axiron net sales of US\$36.3 million in its financial results for the quarter ended 30 September 2014.

Axiron net sales for the 2014 calendar year to date are shown in the following table:

Q1 2014	Q2 2014	Q3 2014	Total to date
US\$39.5m	US\$47.1m	US\$36.3m	US\$122.9m

Net Sales reported by Lilly for the previous corresponding year to date were US\$124.8 million.

### Contact

Ross Dobinson, Chairman: 03 9691 5920

### About Acrux

[www.acrux.com.au](http://www.acrux.com.au)

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- The Acrux technology, used in marketed products including AXIRON®, Evamist® and Recuvyra™, is based on a fast-drying, small volume, accurately dosed solution, containing penetration enhancers, that when applied topically, deposit drug through the skin for long acting delivery.
- Acrux has three products marketed by licensees in the USA, three products approved in Europe, and further products at earlier stages of development.